肝移植的未来:采访Pierre-Alain Clavien。

IF 1.2 Q4 ONCOLOGY Hepatic Oncology Pub Date : 2020-06-22 DOI:10.2217/hep-2020-0021

Pierre-Alain Clavien

{"title":"肝移植的未来:采访Pierre-Alain Clavien。","authors":"Pierre-Alain Clavien","doi":"10.2217/hep-2020-0021","DOIUrl":null,"url":null,"abstract":"In this interview, we catch up with Hepatic Oncology board member Pierre-Alain Clavien to discuss his involvement in the development of an integrated perfusion machine capable of preserving livers outside of the body for up to 1 week. The development could have huge implications for the future of liver transplantation as it is hoped it could allow more patients access to vital transplants.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"7 2","pages":"HEP23"},"PeriodicalIF":1.2000,"publicationDate":"2020-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/hep-2020-0021","citationCount":"0","resultStr":"{\"title\":\"The future of liver transplantation: an interview with Pierre-Alain Clavien.\",\"authors\":\"Pierre-Alain Clavien\",\"doi\":\"10.2217/hep-2020-0021\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In this interview, we catch up with Hepatic Oncology board member Pierre-Alain Clavien to discuss his involvement in the development of an integrated perfusion machine capable of preserving livers outside of the body for up to 1 week. The development could have huge implications for the future of liver transplantation as it is hoped it could allow more patients access to vital transplants.\",\"PeriodicalId\":44854,\"journal\":{\"name\":\"Hepatic Oncology\",\"volume\":\"7 2\",\"pages\":\"HEP23\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2020-06-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2217/hep-2020-0021\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hepatic Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/hep-2020-0021\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatic Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/hep-2020-0021","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

在这次采访中，我们采访了肝脏肿瘤学董事会成员Pierre-Alain Clavien，讨论了他参与开发的一种集成灌注机，该灌注机能够在体外保存肝脏长达1周。这一进展可能对肝移植的未来产生巨大影响，因为它有望让更多的患者获得重要的移植手术。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

The future of liver transplantation: an interview with Pierre-Alain Clavien.

In this interview, we catch up with Hepatic Oncology board member Pierre-Alain Clavien to discuss his involvement in the development of an integrated perfusion machine capable of preserving livers outside of the body for up to 1 week. The development could have huge implications for the future of liver transplantation as it is hoped it could allow more patients access to vital transplants.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Hepatic Oncology ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.